Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia: A cancer and leukemia group B study

Cancer

Volumn 101, Issue 2, 2004, Pages 370-378

  Burns, C Patrick ^a,b   Halabi, Susan ^c   Clamon, Gerald ^a,b   Kaplan, Ellen ^c   Hohl, Raymond J ^a,b   Atkins, James N ^d   Schwartz, Michael A ^e   Wagner, Brett A ^a,b   Paskett, Electra ^f  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c Cancer and Leukemia Group B Statistical Center   (United States)

^d SE Cancer Control Consortium Inc ^*  (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer cachexia; Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil capsules; Omega 3 fatty acids

Indexed keywords

ALBUMIN; CREATININE; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PREALBUMIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CACHEXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DRUG CAPSULE; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKEMIA; LIPID COMPOSITION; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SOLID TUMOR; TASTE DISORDER; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; CACHEXIA; CAPSULES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREALBUMIN; QUALITY OF LIFE; WEIGHT GAIN;

EID: 3042702471     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20362     Document Type: Article

References (28)

1. Russell ST, Tisdale MJ. Effect of a tumour-derived lipidmobilising factor on glucose and lipid metabolism in vivo. Br J Cancer. 2002;87:580-584.
2. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature. 1996;379:739-742.
3. Tisdale MJ, Dhesi JK. Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model. Cancer Res. 1990;50:5022-5026.
4. Dagnelie PC, Bell JD, Williams SC, Bates TE, Abel PD, Foster CS. Effect of fish oil on cancer cachexia and host liver metabolism in rats with prostate tumors. Lipids. 1994;29:195-203.
5. Beck SA, Smith KL, Tisdale MJ, Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991;51:6089-6093.
6. Wigmore SI, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177-184.
7. Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer. 1998;82:395-402.
8. Burns CP, Halabi S, Clamon GH, et al. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and Leukemia Group B study 9473. Clin Cancer Res. 1999;5:3942-3947.
9. Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003;21:129-134.
10. Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479-1486.
11. Jatoi A, Rowland KM, Loprinzi CL, et al. An eicosapentaenoic acid (EPA)-enriched supplement versus megestrol acetate (MA) versus both for patients with cancer-associated wasting. A collaborative effort from the North Central Cancer Treatment Group (NCCTG) and the National Cancer Institute of Canada [abstract]. Proc Am Soc Clin Oncol. 2003;22:743.
12. Burns CP, Petersen ES, North JA, Ingraham LM. Effect of docosahexaenoic acid on rate of differentiation of HL-60 human leukemia. Cancer Res. 1989;49:3252-3258.
13. Burns CP, Wagner BA. Heightened susceptibility of fish oil polyunsaturate-enriched neoplastic cells to ethane generation during lipid peroxidation. J Lipid Res. 1991;32:79-87.
14. Ribaudo JM, Cella D, Hahn EA, et al. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res. 2000;9:1137-1146.
15. Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF. Nutritional and metabolic assessment of the hospitalized patient. JPEN J Parenter Enteral Nutr. 1977;1:11-22.
16. Whitehouse AS, Smith HJ, Drake JL, Tisdale MI. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 2001;61:3604-3609.
17. Pratt VC, Watanabe S, Bruera E, et al. Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. Br J Cancer. 2002;87:1370-1378.
18. Wigmore SJ, Ross JA, Falconer IS, et al. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition. 1996;12(1 Suppl):S27-S30.
19. Burns CP, Spector AA. Effects of lipids on cancer therapy. Nutr Rev. 1990;48:233-240.
20. Spector AA, Burns CP. Biological and therapeutic potential of membrane lipid modification in tumors. Cancer Res. 1987;47:4529-4537.
21. Tchekmedyian NS, Tait N, Moody M, Aisner J. High-dose megestrol acetate. A possible treatment for cachexia. JAMA. 1987;257:1195-1198.
22. Simons JP, Aaronson NK, Vansteenkiste JF, et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol. 1996;14:1077-1084.
23. De Conno F, Martini C, Zecca E, et al. Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer. 1998;34:1705-1709.
24. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82:1127-1132.
25. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990;66:1279-1282.
26. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993;11:152-154.
27. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999;81:80-86.
28. MacDonald N. Is there evidence for earlier intervention in cancer-associated weight loss? J Support Oncol. 2003;1:279-286.